DOCSLIB.ORG

Identification of Pathogenic Gene Mutations in LMNA and MYBPC3 That Alter RNA Splicing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Pathogenic Gene Mutations in LMNA and MYBPC3 That Alter RNA Splicing Identification of pathogenic gene mutations in LMNA and MYBPC3 that alter RNA splicing Kaoru Itoa,1, Parth N. Patela, Joshua M. Gorhama, Barbara McDonougha,b, Steven R. DePalmaa,b, Emily E. Adlera, Lien Lama, Calum A. MacRaec, Syed M. Mohiuddind, Diane Fatkine,f,g, Christine E. Seidmana,b,c,2, and J. G. Seidmana,2,3 aDepartment of Genetics, Harvard Medical School, Boston, MA 02115; bHoward Hughes Medical Institute, Harvard Medical School, Boston, MA 02115; cCardiovascular Division, Brigham and Women’s Hospital, Boston, MA 02115; dDepartment of Internal Medicine, Creighton University Medical Center, Omaha, NE 68131; eFaculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia; fVictor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia; and gCardiology Department, St Vincent’s Hospital, Darlinghurst, NSW 2010, Australia Contributed by J. G. Seidman, June 9, 2017 (sent for review May 16, 2017; reviewed by Gerald Dorn and Jil C. Tardiff) Genetic variants that cause haploinsufficiency account for many cost and time constraints limit their application to clinical gene- autosomal dominant (AD) disorders. Gene-based diagnosis classifies based diagnosis (6, 7). variants that alter canonical splice signals as pathogenic, but due to imperfect understanding of RNA splice signals other variants that Results maycreateoreliminatesplicesites are often clinically classified as LMNA and MYBPC3 Variants That Affect RNA Splicing. LoF variants in variants of unknown significance (VUS). To improve recognition of LMNA and MYBPC3 are prevalent causes of dilated cardiomyop- pathogenic splice-altering variants in AD disorders, we used compu- athy (DCM) with associated conduction defects (8) and hypertro- tational tools to prioritize VUS and developed a cell-based minigene phic cardiomyopathy (HCM) (9, 10), respectively. Databases report splicing assay to confirm aberrant splicing. Using this two-step 948 unique LMNA and 2,029 unique MYBPC3 variants observed procedure we evaluated all rare variants in two AD cardiomyopathy Materials and LMNA MYBPC3 across cardiomyopathy patients and normal subjects ( genes, lamin A/C ( ) and myosin binding protein C ( ). Methods We demonstrate that 13 LMNA and 35 MYBPC3 variants identified in ). Among these, we sought to identify splice-altering vari- cardiomyopathy patients alter RNA splicing, representing a 50% in- ants. After excluding all LoF variants (nonsense, frameshifts, and crease in the numbers of established damaging splice variants in variants that alter canonical donor GT and acceptor AG splice these genes. Over half of these variants are annotated as VUS by sequences)andcommonvariants (allele frequency >0.003; LMNA MEDICAL SCIENCES clinical diagnostic laboratories. Familial analyses of one variant, a n = 133; MYBPC3 n = 454, Table S1), we identified 815 LMNA synonymous LMNA VUS, demonstrated segregation with cardiomy- and 1575 MYBPC3 rare missense, synonymous, and intronic vari- opathy affection status and altered cardiac LMNA splicing. Applica- ants for study. tion of this strategy should improve diagnostic accuracy and variant First, we prioritized variants using a computational algorithm to classification in other haploinsufficient AD disorders. calculate MaxEnt scores (11), which are computed as the “dis- tance” from splice signals found in human genes (Materials and VUS | splicing | cardiomyopathy | LMNA | MYBPC3 Methods and Fig. S1). Based on the calculated MaxEnt scores for 815 LMNA (Dataset S1)and1,575MYBPC3 variants (Dataset S2), NA sequence analysis of patient DNA has been used to Dclinically diagnose associated inherited diseases, leading to the Significance identification of thousands of rare sequence variants in affected and unaffected individuals. Interpreting the medical significance of Sequence variants that create or eliminate splice sites are often these variants has proven to be a significant challenge. The anno- clinically classified as variants of unknown significance (VUS) due tation of nonsense, frameshift, insertion, and deletion variants that to imperfect understanding of RNA splice signals and cumber- cause a highly predictable outcome [i.e., loss of function (LoF) of some functional assays. In autosomal dominant disorders caused proteins encoded by disease genes] allows these to be clinically by haploinsufficiency, variants that alter normal splicing of one classified as pathogenic variants in more than 4,000 genes that allele are pathogenic. We developed enhanced computational cause disease by haploinsufficiency (1). Classification of rare syn- tools to prioritize potential splice-altering VUS and used a mini- onymous and missense variants in these genes, however, has been gene assay to functionally confirm splice-altering sequence vari- more difficult. Although bioinformatic algorithms predict that ants. In studying all reported variants across LMNA and MYBPC3, some variants may damage the encoded protein, these annotations two known heart disease genes, we demonstrate that ∼5% of are imperfect, and many rare variants remain unclassified and are VUS from affected patients alter splicing and are undetected clinically designated as variants of unknown significance (VUS) (2). disease-causing variants. This strategy improves clinical detection Splicing signals reside at all exon–intron junctions and include a of pathogenic variants and should be broadly relevant to other 9-bp 5′ splice donor sequence with an invariant GT dinucleotide human disorders that are caused by haploinsufficiency. and a 23-bp 3′ splice acceptor sequence with an invariant AG di- nucleotide (3) (Fig. 1A). Variants that alter the canonical GT and Author contributions: K.I., J.M.G., C.E.S., and J.G.S. designed research; K.I., P.N.P., J.M.G., AG dinucleotides in haploinsufficient autosomal dominant (AD) B.M., E.E.A., L.L., C.A.M., S.M.M., and D.F. performed research; K.I., P.N.P., S.R.D., and J.G.S. analyzed data; and K.I., P.N.P., C.E.S., and J.G.S. wrote the paper. genes are diagnostically classified as pathogenic, whereas substitu- tions of the remaining seven residues within the donor sequence, or Reviewers: G.D., Washington University; and J.C.T., University of Arizona. the 21 residues within the acceptor sequence, are often classified as Conflict of interest statement: C.E.S. and J.G.S. are founders of and own shares in Myo- kardia Inc., a startup company that is developing therapeutics that target the sarcomere. VUS (4). VUS that alter these sequences, however, have the po- 1Present address: Laboratory for Cardiovascular Diseases, RIKEN Center for Integrative tential to disrupt normal RNA splicing (5) (resulting in donor or Medical Sciences, Yokohama 230-0045, Japan. C acceptor loss; Fig. 1 ). Similarly, variants within a nearby intron or 2C.E.S. and J.G.S. contributed equally to this work. exon may sufficiently mimic the consensus donor or acceptor sites 3To whom correspondence should be addressed. Email: [email protected]. to generate new, inappropriate splice signals (donor or acceptor harvard.edu. C gain; Fig. 1 ). Although existing in vitro splicing assays can identify This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. variants that alter splicing and thereby identify pathogenic variants, 1073/pnas.1707741114/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1707741114 PNAS Early Edition | 1of6 Downloaded by guest on September 28, 2021 Fig. 1. Schematics of gene splice signals and a functional assay of potential splice-altering variants. (A) A gene segment containing two exons (blue) and flanking introns (gray) with consensus 9-bp splice donor and 23-bp splice acceptor sequences is shown. The nucleotide letter sizes (drawn using Pictogram; genes.mit.edu/ pictogram.html) denote use of that base in splicing across the genome. Dinucleotides GT (donor site) and AG (acceptor site) are invariant. Normally spliced transcript (red) that excludes intron sequence is depicted. (B) Functional assay of splicing candidates used a 1,200-bp minigene construct comprised of CMV promoter, exon– intron–exon sequence, a 2-bp barcode to identify the construct, and SV40polyA sequence. Exon–intron–exon test sequences were encoded on a synthetic 500-bp oligonucleotide that limited the inclusion of intron sequences to 200 bp (further details provided in Materials and Methods and Datasets S3 and S4). A normally spliced minigene-derived transcript (red) that excludes intron sequence is depicted. (C) Splice-altering variants detected by functional assays. Variants that destroy donor or acceptor signals prevent normal splicing (“x”) and yield transcripts with included introns, partial deletions, or entirely skipped exons. [Note that analyses reported excluded all variants that altered the invariant GT (donor site) and AG (acceptor site) sequences.] Variants that create a novel splice signal (donor or acceptor gain, “✓”) inappropriately delete sequences from the 5′ or 3′ exon. Novel splice sites that occur within introns and insert sequences are not depicted. we selected 57 LMNA and 139 MYBPC3 splicing candidates for observed in “normal” subjects. Approximately 0.4% (LMNA: further assessment. 1/395, MYBPC3: 4/767) of rare synonymous, missense, or intronic We developed a cell-based minigene assay to test all splicing variants reported only in normal subjects altered splicing, whereas candidates (Fig. S2). The assay compared RNA transcripts extracted ∼4% (LMNA: 13/420; MYBPC3: 35/808) of such variants reported from HEK293 cells transfected with
Load more

Recommended publications
  • EYS Mutations and Implementation of Minigene Assay for Variant
    www.nature.com/scientificreports OPEN EYS mutations and implementation of minigene assay for variant classifcation in EYS‑associated retinitis pigmentosa in northern Sweden Ida Maria Westin1, Frida Jonsson1, Lennart Österman1, Monica Holmberg1, Marie Burstedt2 & Irina Golovleva1* Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous group of inherited retinal degenerations. The ortholog of Drosophila eyes shut/spacemaker, EYS on chromosome 6q12 is a major genetic cause of recessive RP worldwide, with prevalence of 5 to 30%. In this study, by using targeted NGS, MLPA and Sanger sequencing we uncovered the EYS gene as one of the most common genetic cause of autosomal recessive RP in northern Sweden accounting for at least 16%. The most frequent pathogenic variant was c.8648_8655del that in some patients was identifed in cis with c.1155T>A, indicating Finnish ancestry. We also showed that two novel EYS variants, c.2992_2992+6delinsTG and c.3877+1G>A caused exon skipping in human embryonic kidney cells, HEK293T and in retinal pigment epithelium cells, ARPE‑19 demonstrating that in vitro minigene assay is a straightforward tool for the analysis of intronic variants. We conclude, that whenever it is possible, functional testing is of great value for classifcation of intronic EYS variants and the following molecular testing of family members, their genetic counselling, and inclusion of RP patients to future treatment studies. Retinitis pigmentosa (RP, MIM 268000) is a clinically and genetically heterogeneous group of inherited retinal degenerations (IRDs) causing primarily deterioration of the rod photoreceptors with subsequent worsening of the cones. It is classifed into two forms: syndromic (afecting other organs) and non-syndromic (not afect- ing other organs).
    [Show full text]
  • Cellular Minigene Models for the Study of Allelic Expression of the Tau Gene and Its Role in Progressive Supranuclear Palsy
    CELLULAR MINIGENE MODELS FOR THE STUDY OF ALLELIC EXPRESSION OF THE TAU GENE AND ITS ROLE IN PROGRESSIVE SUPRANUCLEAR PALSY Victoria Anne Kay Thesis submitted in the fulfilment of the degree of Doctor of Philosophy Reta Lila Weston Institute of Neurological Studies Institute of Neurology University College London March 2013 Declaration I, Victoria Kay, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Progressive supranuclear palsy (PSP) belongs to a group of neurodegenerative disorders that are characterised by hallmark pathology consisting of intra-neuronal aggregates of the microtubule-associated protein, tau. In PSP, these aggregates are almost exclusively composed of one of the two major tau protein isoform groups normally expressed at similar levels in the healthy brain, indicating a role for altered isoform regulation in PSP aetiology. Although no causal mutations have been identified, common variation within the gene encoding tau, MAPT, has been highly associated with PSP risk. The A-allele of the rs242557 single nucleotide polymorphism has been repeatedly shown to significantly increase the risk of developing PSP. Its location within a distal region of the MAPT promoter region is significant, with independent studies – including this one – demonstrating that the rs242557-A allele alters the function of a transcription regulatory domain. As transcription and alternative splicing processes have been shown to be co-regulated in some genes, it was hypothesised that the rs242557-A allele could directly affect MAPT alternative splicing through its differential effect on transcription.
    [Show full text]
  • Splicing Inhibition of U2AF Leads to Alternative Exon Skipping
    Splicing inhibition of U2AF65 leads to alternative exon skipping Sunghee Choa, Heegyum Moona, Tiing Jen Loha, Ha Na Janga, Yongchao Liua, Jianhua Zhoub, Takbum Ohnc, Xuexiu Zhenga, and Haihong Shena,1 aSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea; bJiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, China; and cDepartment of Cellular & Molecular Medicine, College of Medicine, Chosun University, Gwangju 501-759, Korea Edited by Michael R. Green, University of Massachusetts Medical School, Worcester, MA, and approved June 11, 2015 (received for review January 11, 2015) U2 snRNP auxiliary factor 65 kDa (U2AF65) is a general splicing factor mutations in SMN2 pre-mRNA cause predominantly skipping of that contacts polypyrimidine (Py) tract and promotes prespliceo- exon 7, which produces SMNΔ7, a truncated and less stable pro- some assembly. In this report, we show that U2AF65 stimulates al- tein with reduced self-oligomerization activity. Alternative exon 7 ternative exon skipping in spinal muscular atrophy (SMA)-related splicing of SMN pre-mRNA was modulated by orchestrated RNA– survival motor neuron (SMN) pre-mRNA. A stronger 5′ splice-site protein and protein–protein interactions, secondary structures of mutation of alternative exon abolishes the stimulatory effects of RNA, and RNA sequences (25–27). Among the mutations on U2AF65. U2AF65 overexpression promotes its own binding only on SMN2 pre-mRNA, the most functionally understood one is the the weaker, not the stronger, Py tract. We further demonstrate C-to-U point mutation on exon 7, which plays an important role in that U2AF65 inhibits splicing of flanking introns of alternative exon alternative splicing of exon 7 (25–27).
    [Show full text]
  • An Inhibitory Intron to a Stimulatory Intron by Alteration of the Splice Donor Sequence
    Nucleic Acids Research, 1993, Vol. 21, No. 25 5901-5908 Stimulation of gene expression by introns: conversion of an inhibitory intron to a stimulatory intron by alteration of the splice donor sequence Martin Korb+, Yunbo Ke and Lee F.Johnson* Departments of Molecular Genetics and Biochemistry, The Ohio State University, Columbus, OH 43210, USA Received September 16, 1993; Revised and Accepted November 18, 1993 GenBank accession no. L11364 ABSTRACT Efficient expression of many mammalian genes Introns have been shown to be directly responsible for a variety depends on the presence of at least one intron. We of qualitative changes in gene expression. For example, previously showed that addition of almost any of the alternative splicing of introns from primary transcripts can give introns from the mouse thymidylate synthase (TS) gene rise to multiple mRNA (and protein) species from a single gene to an intronless TS minigene led to a large increase In (reviewed in 3). expression. However, addition of intron 4 led to a Introns can also have quantitative effects on gene expression. reduction In minigene expression. The goal of the Some introns contain promoter or enhancer elements and present study was to determine why TS intron 4 was stimulate expression by increasing the rate of gene transcription unable to stimulate expression. Insertion of intron 4 (4-12). Regulating the efficiency of intron splicing also appears into an intron-dependent derivative of the ribosomal to play an important role in the autogenous regulation of yeast protein L32 gene did not lead to a significant increase ribosomal protein genes (13), and in the growth-regulated in expression, suggesting that its inability to stimulate expression of several mammalian genes for S-phase proteins expression was due to sequences within the intron.
    [Show full text]
  • Independence Between Pre-Mrna Splicing and De Novo DNA Methylation in an Isogenic Minigene Resource
    bioRxiv preprint doi: https://doi.org/10.1101/124073; this version posted April 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Independence between pre-mRNA splicing and de novo DNA methylation in an isogenic minigene resource Kyster K. Nanan1, Cody Ocheltree1, David Sturgill1, Mariana D. Mandler1, Maria Prigge1, Garima Varma1,2 and Shalini Oberdoerffer1,* 1 Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, U.S.A. 2 Current address, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, 19107, U.S.A. * To whom correspondence should be addressed. Tel: 001-240-760-6682; Fax: 301-496-4951; Email: [email protected]. ABSTRACT Actively transcribed genes adopt a unique chromatin environment with characteristic patterns of enrichment. Within gene bodies, H3K36me3 and cytosine DNA methylation are elevated at exons of spliced genes and have been implicated in the regulation of pre-mRNA splicing. H3K36me3 is further responsive to splicing, wherein splicing inhibition led to a redistribution and general reduction over gene bodies. In contrast, little is known of the mechanisms supporting elevated DNA methylation at actively spliced genic locations. Recent evidence associating the de novo DNA methyltransferase Dnmt3b with H3K36me3-rich chromatin raises the possibility that genic DNA methylation is influenced by splicing-associated H3K36me3. Here, we report the generation of an isogenic resource to test the direct impact of splicing on chromatin. A panel of minigenes of varying splicing potential were integrated into a single FRT site for inducible expression.
    [Show full text]
  • Splicing Inhibition of U2AF Leads to Alternative Exon Skipping
    Splicing inhibition of U2AF65 leads to alternative exon skipping Sunghee Choa, Heegyum Moona, Tiing Jen Loha, Ha Na Janga, Yongchao Liua, Jianhua Zhoub, Takbum Ohnc, Xuexiu Zhenga, and Haihong Shena,1 aSchool of Life Sciences, Gwangju Institute of Science and Technology, Gwangju 500-712, Korea; bJiangSu Key Laboratory of Neuroregeneration, Nantong University, Nantong 226001, China; and cDepartment of Cellular & Molecular Medicine, College of Medicine, Chosun University, Gwangju 501-759, Korea Edited by Michael R. Green, University of Massachusetts Medical School, Worcester, MA, and approved June 11, 2015 (received for review January 11, 2015) U2 snRNP auxiliary factor 65 kDa (U2AF65) is a general splicing factor mutations in SMN2 pre-mRNA cause predominantly skipping of that contacts polypyrimidine (Py) tract and promotes prespliceo- exon 7, which produces SMNΔ7, a truncated and less stable pro- some assembly. In this report, we show that U2AF65 stimulates al- tein with reduced self-oligomerization activity. Alternative exon 7 ternative exon skipping in spinal muscular atrophy (SMA)-related splicing of SMN pre-mRNA was modulated by orchestrated RNA– survival motor neuron (SMN) pre-mRNA. A stronger 5′ splice-site protein and protein–protein interactions, secondary structures of mutation of alternative exon abolishes the stimulatory effects of RNA, and RNA sequences (25–27). Among the mutations on U2AF65. U2AF65 overexpression promotes its own binding only on SMN2 pre-mRNA, the most functionally understood one is the the weaker, not the stronger, Py tract. We further demonstrate C-to-U point mutation on exon 7, which plays an important role in that U2AF65 inhibits splicing of flanking introns of alternative exon alternative splicing of exon 7 (25–27).
    [Show full text]
  • Use of Minigene Systems to Dissect Alternative Splicing Elements
    Methods 37 (2005) 331–340 www.elsevier.com/locate/ymeth Use of minigene systems to dissect alternative splicing elements Thomas A. Cooper * Departments of Pathology and Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA Accepted 5 July 2005 Abstract Pre-mRNA splicing is an essential step for gene expression in higher eukaryotes. The splicing efficiency of individual exons is deter- mined by multiple features involving gene architecture, a variety of cis-acting elements within the exons and flanking introns, and interactions with components of the basal splicing machinery (called the spliceosome) and auxiliary regulatory factors which transiently co-assemble with the spliceosome. Both alternative and constitutive exons are recognized by multiple weak protein:RNA interactions and different exons differ in the interactions which are determinative for exon usage. Alternative exons are often regulated according to cell-specific patterns and regulation is mediated by specific sets of cis-acting elements and trans-acting factors. Transient expression of minigenes is a commonly used in vivo assay to identify the intrinsic features of a gene that control exon usage, identify specific cis-acting elements that control usage of constitutive and alternative exons, identify cis-acting elements that control cell-specific usage of alternative exons, and once regulatory elements have been identified, to identify the trans-acting factors that bind to these elements and modulate splicing. This chapter describes approaches and strategies for using minigenes to define the cis-acting elements that determine splice site usage and to identify and characterize the trans-acting factors that bind to these elements and regulate alternative splicing.
    [Show full text]
  • Cell-Based Splicing of Minigenes
    Chapter 18 Cell-Based Splicing of Minigenes Sarah A. Smith and Kristen W. Lynch Abstract Cell-based splicing of minigenes is used extensively in the analysis of alternative splicing events. In particular, such assays are critical for identifying or confi rming the in vivo relevance of cis - and trans -acting factors in the regulation of particular splicing patterns. Here we provide detailed information on the methods specifi c to the cell-based analysis of minigene splicing. In addition, we discuss some of the theoretical considerations that must be given to the design of the minigene and subsequent experimental conditions. Key words Minigene , RNA isolation , RT-PCR , Transfection , Stable cell lines , Alternative splicing , Exon , Intron 1 Introduction The use of minigenes has long been a central tool in the character- ization of splicing regulation and mechanisms. As the name implies, a “minigene” is a simplifi ed version of an endogenous pre-mRNA. Most pre-mRNAs are vastly too long for ready manipulation, and mutation of endogenous genes in living cells is both ineffi cient and potential toxic. Therefore, use of a simplifi ed model of a pre- mRNA, or “minigene,” opens the door to lines of investigation not other- wise feasible. Indeed, the vast majority of known sequence elements that control pre-mRNA splicing were identifi ed and/or character- ized through minigene studies (e.g., [ 1 – 3 ]). Minigenes are also widely used to report on splicing patterns in cell-based screens for trans-acting proteins and regulatory pathways (e.g., [ 4 – 6 ]). At the point at which one has identifi ed a splicing event of interest—perhaps a change in the alternative splicing pattern of a particular gene in normal and diseased cells—the next step in understanding how the splicing pattern is regulated is most typi- cally the development and characterization of a minigene.
    [Show full text]
  • Splicing: Going in Circles
    RESEARCH HIGHLIGHTS Nature Reviews Molecular Cell Biology | Published online 6 Dec 2017; doi:10.1038/nrm.2017.128 SPLICING V. Summersby/Macmillan V. Publishers Limited Going in circles Circular RNAs (circRNAs) are covalently closed RNAs that can specifically control gene expression. CircRNAs are produced at low levels from many failure to protein-coding genes by pre-mRNA ‘back-splicing’ of exons, but the terminate mechanisms that modulate their production are poorly understood. Liang et al. now show that steady-state circRNA levels increase when co-transcriptional transcription mRNA processing is diminished. can result The authors introduced into fruit fly DL1 cells a three-exon minigene derived in circRNA from the laccase2 gene, which is known to produce circRNA. Depletion of production several spliceosome proteins largely eliminated the expression of the minigene linear mRNA. By contrast, expression of the minigene circRNA in these cells was from only slightly decreased or even increased. Importantly, the splicing patterns of downstream the endogenous laccase2 gene and of two other circRNA-producing genes genes were similarly affected. Furthermore, the depletion of 25 other core spliceosome proteins resulted in increase in circRNA expression from various endogenous genes. These data suggested that the relative efficiency of back-splicing compared with canonical splicing increases when the quantity of spliceosome proteins is limited. Next, the authors examined the effect of mRNA 3ʹ-end processing on circRNA production. Depletion of the cleavage and polyadenylation factors Cpsf73 (cleavage and polyadenylation specificity factor 73) and Symplekin greatly increased the expression of the minigene circRNA. Gene expression analyses revealed that depleting these factors reduced transcription termination of an upstream gene, which resulted in readthrough transcription into the minigene and back-splicing.
    [Show full text]
  • Hybrid Minigene Splicing Assay Verifies the Pathogenicity of a Novel
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Xiamen University Institutional Repository Injury 50 (2019) 2215–2219 Contents lists available at ScienceDirect Injury journal homepage: www.elsevier.com/locate/injury Hybrid minigene splicing assay verifies the pathogenicity of a novel splice site variant in the COL1A1 gene of a chinese patient with osteogenesis imperfecta type I Yuxiang Lin 1, Xiaoli Li 1, Xinghua Huang, Dezhu Zheng, Yichu Liu, Fenghua Lan, ∗ Zhihong Wang Research Center for Molecular Diagnosis of Genetic Diseases, Dongfang Hospital, Xiamen University Medical College, Fuzhou, China a r t i c l e i n f o a b s t r a c t Article history: Background: Osteogenesis imperfecta (OI) is a rare genetic bone disease associated with brittle bones and Accepted 14 October 2019 fractures. Among all known types, OI type I is the most common type and characterized by increased bone fragility, low bone mass, distinctly blue-gray sclera, and susceptibility to conductive hearing loss Keywords: beginning in adolescence. Mutations in genes encoding type I collagen ( COL1A1 and COL1A2 ) contribute Bioinformatics to the main pathogenic mechanism of OI. Osteogenesis imperfecta type I Methods: Subtle mutation of the COL1A1 gene in the proband was detected by targeted next-generation Hybrid minigene splicing assay sequencing (NGS) and confirmed by Sanger sequencing. We then assessed the effect of the mutation on Next-generation sequencing the splicing of the COL1A1 gene by bioinformatics prediction and hybrid minigene splicing assay (HMSA). Results: A novel splice site mutation c.1821 + 1 G > C was discovered in the proband by NGS and further confirmed by Sanger sequencing, which was also simultaneously identified from the proband’s mother and elder sister.
    [Show full text]
  • Using Positional Distribution to Identify Splicing Elements and Predict Pre-Mrna Processing Defects in Human Genes
    Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes Kian Huat Lima, Luciana Ferrarisa, Madeleine E. Fillouxa, Benjamin J. Raphaelb,c, and William G. Fairbrothera,c,d,1 aDepartment of Molecular and Cellular Biology and Biochemistry, Brown University, 70 Ship Street, Providence, RI 02903; bDepartment of Computer Science, Brown University, Providence, RI 02912; cCenter for Computational Molecular Biology, 151 Waterman Street, Providence, RI 02912; and dCenter for Genomics and Proteomics, Brown University, 70 Ship Street, Providence, RI 02903 Edited by Phillip A. Sharp, MIT, Cambridge, MA, and approved May 13, 2011 (received for review February 11, 2011) We present an intuitive strategy for predicting the effect of molecular intervention. As physical methods for the detection of sequence variation on splicing. In contrast to transcriptional ele- alternative splicing require large panels of genotyped accessible ments, splicing elements appear to be strongly position dependent. tissue, these studies will probably continue to be limited to sam- We demonstrated that exonic binding of the normally intronic spli- ples harvested from human blood. An alternate approach is the cing factor, U2AF65, inhibits splicing. Reasoning that the positional prediction of causative variations from single-nucleo polymorph- distribution of a splicing element is a signature of its function, we ism (SNPs) that fall within splicing elements. The key to this developed a method for organizing all possible sequence motifs approach is being able to identify what the splicing elements into clusters based on the genomic profile of their positional dis- are and whether a variation is disruptive. tribution around splice sites.
    [Show full text]
  • The Conserved 39 End Domain of U6atac Snrna Can Direct U6 Snrna to the Minor Spliceosome
    Downloaded from rnajournal.cshlp.org on September 26, 2021 - Published by Cold Spring Harbor Laboratory Press The conserved 39 end domain of U6atac snRNA can direct U6 snRNA to the minor spliceosome ROSEMARY C. DIETRICH,1 RICHARD A. PADGETT,1 and GIRISH C. SHUKLA2 1Department of Molecular Genetics, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA 2Center for Gene Regulation in Health and Disease, Department of Biological, Geological, and Environmental Sciences, Cleveland State University, Cleveland, Ohio 44115, USA ABSTRACT U6 and U6atac snRNAs play analogous critical roles in the major U2-dependent and minor U12-dependent spliceosomes, respectively. Previous results have shown that most of the functional cores of these two snRNAs are either highly similar in sequence or functionally interchangeable. Thus, a mechanism must exist to restrict each snRNA to its own spliceosome. Here we show that a chimeric U6 snRNA containing the unique and highly conserved 39 end domain of U6atac snRNA is able to function in vivo in U12-dependent spliceosomal splicing. Function of this chimera required the coexpression of a modified U4atac snRNA; U4 snRNA could not substitute. Partial deletions of this element in vivo, as well as in vitro antisense experiments, showed that the 39 end domain of U6atac snRNA is necessary to direct the U4atac/U6atac.U5 tri-snRNP to the forming U12-dependent spliceosome. In vitro experiments also uncovered a role for U4atac snRNA in this targeting. Keywords: RNA–RNA interactions; U2-dependent splicing; pre-mRNA INTRODUCTION The four snRNAs that are unique to each spliceosome have been shown to be functional analogs.
    [Show full text]